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Abstract
Background:  Mammalian cells have been reported to have a p53-dependent tetraploidy
checkpoint that blocks cell cycle progression in G1 in response to failure of cell division. In most
cases where the tetraploidy checkpoint has been observed cell division was perturbed by anti-
cytoskeleton drug treatments. However, other evidence argues against the existence of a
tetraploidy checkpoint. Cells that have failed to divide differ from normal cells in having two nuclei,
two centrosomes, a decreased surface to volume ratio, and having undergone an abortive
cytokinesis. We tested each of these to determine which, if any, cause a G1 cell cycle arrest.
Results: Primary human diploid fibroblasts with intact cell cycle checkpoints were used in all
experiments. Synchronized cells exhibited G1 arrest in response to division failure caused by
treatment with either cytochalasin or the myosin II inhibitor blebbistatin. The role of tetraploidy,
aberrant centrosome number, and increased cell size were tested by cell/cell and cell/cytoplast
fusion experiments; none of these conditions resulted in G1 arrest. Instead we found that various
drug treatments of the cells resulted in cellular damage, which was the likely cause of the arrest.
When cytokinesis was blocked in the absence of damage-inducing drug treatments no G1 arrest
was observed.
Conclusions: We show that neither tetraploidy, aberrant centrosome number, cell size, nor
failure of cytokinesis lead to G1 arrest, suggesting that there is no tetraploidy checkpoint. Rather,
certain standard synchronization treatments cause damage that is the likely cause of G1 arrest.
Since tetraploid cells can cycle when created with minimal manipulation, previous reports of a
tetraploidy checkpoint can probably be explained by side effects of the drug treatments used to
observe them.
Background
Cell cycle checkpoints preserve genome integrity by mon-
itoring the fidelity of DNA replication and segregation. In
mammalian somatic cells, the best-characterized check-
points are the DNA damage/replication checkpoints and
the mitotic spindle checkpoint. The DNA damage/replica-
tion checkpoints result in cell cycle arrest if DNA is not
fully replicated, or is damaged [1]. The mitotic spindle
checkpoint results in cell cycle arrest prior to anaphase if
the spindle is not properly assembled [2].
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There is also evidence that defects in events relating to cell
division itself can result in cell cycle arrest. Lanni and Jacks
[3] and Casenghi et al.[4] found that mammalian cells
that had adapted to microtubule depolymerization and
exited mitosis without undergoing cytokinesis arrested in
G1 of the subsequent cell cycle. Kurimura and Hirano [5]
and Andreassen et al. [6] reported that inhibition of cyto-
kinesis with the actin-depolymerizing drug cytochalasin
resulted in a similar arrest in G1 of the subsequent cell
cycle. These treatments resulted in cells that were tetra-
ploid, and Andreassen et al. [6] proposed that the cell
cycle arrest was triggered by ploidy, terming this effect a
"tetraploidy checkpoint".
Other evidence suggests that mammalian cells are not sen-
sitive to tetraploidy. Rao and Johnson used cell fusion to
study the regulation of DNA synthesis and mitosis by fus-
ing cells at different cell cycle stages [7,8]. Binucleate tetra-
ploid cells resulting from fusion between cells in different
cell cycle stages were able to progress through the cell
cycle. Uetake and Sluder ([9], reviewed in [10]) reported
that inhibition of cytokinesis with a low dose of cytocha-
lasin also allowed cell cycle progression. Most strikingly,
there are rare cases of human infants born with fully tetra-
ploid karyotypes [11]. Although these individuals have
severe defects, their existence argues against tetraploidy as
a trigger for cell cycle arrest.
Here we investigate whether tetraploidy or other cellular
defects in binucleate cells lead to cell cycle arrest. We show
that neither tetraploidy, aberrant centrosome number,
cell size, nor failure of cytokinesis lead to G1 arrest, sug-
gesting that there is no tetraploidy checkpoint. Rather, cer-
tain standard synchronization treatments cause DNA
damage that is the likely cause of G1 arrest.
Results and discussion
Immortalized cell lines often have altered checkpoints,
therefore we used early passage primary cells to investigate
the tetraploidy checkpoint. All experiments were per-
formed with human diploid fibroblasts (HDF) from
infant foreskin and used prior to passage 10. We had pre-
viously developed methods for synchronizing these cells
[12], and tested them here for the presence of normal
checkpoint mechanisms. First, the levels of p53 were
determined by western blotting and found to be similar to
other p53+/+ cell lines (not shown). Second, we tested for
a functional DNA damage response. G1 phase HDF cells
were released from serum starvation and irradiated with
ultraviolet (UV) light. The cells were then assayed for
entry into S phase by 5-bromodeoxyuridine (BrdU) incor-
poration. The HDF cells exhibited a normal DNA damage
response; at a low dose of UV, cells were delayed by about
12 h for entry into S phase, and at a higher dose most cells
did not enter S phase even 36 h after irradiation (Figure
1A). Third, we tested for a functional spindle checkpoint.
Exponentially-growing HDF cells were treated with noco-
dazole for 12 h to depolymerize microtubules, and
assayed by light microscopy. Nocodazole treatment
caused a 6-fold increase in the mitotic index, indicating
that the cells had a functional spindle checkpoint.
We first tested HDF cells for the previously described G1
arrest following cytochalasin-induced failure of cytokine-
sis [6]. Cells were synchronized in mitosis by double thy-
midine arrest followed by nocodazole treatment (Figure
1B), then released for 30 min, after which most cells had
a bipolar spindle. Cells were then allowed to proceed into
interphase in medium containing BrdU, +/- 2 µM cytoch-
alasin. By 10 h after the addition of cytochalasin, both
control and cytochalasin-treated cells had exited mitosis;
approximately 30% of the cytochalasin-treated cells had
two nuclei (binucleate) (Figure 1C) and the remainder
had a single nucleus (mononucleate), presumably having
completed cytokinesis successfully. Thus there were two
types of control cells in these experiments: cells that had
not experienced the drug, and cells that had experienced
the drug, but remained mononucleate. The cultures were
washed at this point to remove drug and allowed to pro-
ceed in the cell cycle.
At 6 h after the removal of cytochalasin, 50% of the
untreated control cells had entered S phase, whereas only
about 10% of either the mononucleate or binucleate cyto-
chalasin-treated cells had entered S phase (Figure 1D);
these numbers changed only slightly by 12 h. However, at
24 h after cytochalasin removal, 75% of the control cells
and 44% of the mononucleate cytochalasin-treated cells
had entered S phase, whereas only 11% of the cytochala-
sin-treated binucleate cells had entered S phase. Similar
results were obtained with 5 µM and 10 µM cytochalasin
(not shown). Thus, binucleate HDF cells resulting from
cytochalasin-induced failure of cytokinesis did arrest in
G1, as previously described for other cells [6].
A potential problem with cytochalasin treatment is that
depolymerization of the actin cytoskeleton is likely to
have effects other than blocking cytokinesis. Indeed, we
found that even at 2 µM, cytochalasin had a strong cyto-
toxic effect, delaying cell cycle progression significantly,
with slow recovery after release (data not shown and
[13]). To determine whether the effect was specific to cyto-
chalasin, the above experiment was repeated using two
other drugs that inhibit cytokinesis: blebbistatin and
aurora kinase inhibitor-1 (AKI-1). Blebbistatin is an
inhibitor of non-muscle myosin II, the motor protein that
provides the force for furrow ingression during cytokinesis
[14]. AKI-1 inhibits the aurora family of kinases, which
play important roles in mitosis and cytokinesis [15].BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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Cell cycle responses of human diploid fibroblast (HDF) cells Figure 1
Cell cycle responses of human diploid fibroblast (HDF) cells. (A) Response to DNA damage. HDF cells were exposed 
to 0, 10 or 20 J/m2 ultraviolet light and entry into S phase was assayed by BrdU incorporation. For each bar n ≥ 300 cells. (B) 
Recovery from nocodazole arrest. HDF cells were arrested in mitosis by double thymidine block followed by nocodazole (left) 
and released for 30 min. (center and right). DNA, blue; α-tubulin, green; γ-tubulin, red. (C) Example of binucleate cells created 
by cytochalasin-induced cytokinesis failure. DNA, blue. (D) Cell cycle progression of HDF cells in response to cytokinesis fail-
ure induced with 2 µM cytochalasin. Cells were assayed for BrdU incorporation at the indicated times after removal of cytoch-
alasin. "control" cells were not treated with cytochalasin; "cytochalasin (mononucleate)" cells were treated, but completed 
cytokinesis, and "cytochalasin (binucleate)" cells were treated and failed to divide in cytokinesis. For each bar n ≥ 300 cells. (E) 
Cell cycle progression of HDF cells in response to cytokinesis failure induced with 12.5 µM blebbistatin. Cells were assayed for 
BrdU incorporation at the indicated times after removal of blebbistatin. "control" cells were not treated with blebbistatin; 
"blebbistatin (mononucleate)" cells were treated, but completed cytokinesis, and "blebbistatin (binucleate)" cells were treated 
and failed to divide in cytokinesis. For each bar n ≥ 300 cells. (F) Cell cycle progression in response to the presence of extra 
centrosomes. Image shows the product of fusion between a G1 cell and a G1 cytoplast. 24 h after fusion this cell has four cen-
trosomes, indicating that it has undergone centrosome duplication, and has incorporated BrdU, indicating that it has entered S 
phase. DNA, blue; BrdU, green; pericentrin, red. Punctate blue staining is due to cell surface marker used to identify fusion 
products [12]. Scale bars represent 10 µm.BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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HDF cells were synchronized in mitosis by double thymi-
dine block followed by nocodazole treatment, then
released into medium containing BrdU, +/- 12.5 µM bleb-
bistatin. By 10 h after the addition of blebbistatin, most
cells had exited mitosis; in the presence of blebbistatin
approximately 30% of the cells were binucleate and the
remaining cells were mononucleate, presumably complet-
ing cytokinesis successfully. Blebbistatin was removed,
and cells were assayed for S phase entry over time.
At 6 h after the removal of blebbistatin, 44% of the
untreated control cells and 53% of the mononucleate
blebbistatin-treated cells had entered S phase, whereas
only 18% of the binucleate blebbistatin-treated cells had
entered S phase (Figure 1E). By 24 h the fraction of both
untreated and blebbistatin-treated mononucleate cells
that had entered S phase rose to about 70%, whereas the
fraction of binucleate cells that had entered S phase
remained at about 20% (Figure 1E). Similar results were
obtained with 25 µM and 50 µM blebbistatin, as well as
with 5 µM AKI-1 (not shown). This indicates that synchro-
nized mitotic cells that failed cytokinesis became arrested
in G1 regardless of the specific inhibitor used.
Cells that have failed to divide after mitosis differ from
normal cells in that they have two nuclei, two centro-
somes, and a decreased surface area to volume ratio. We
tested each of these defects individually for an effect on
G1 arrest. To test the role of centrosome number, serum-
starved G0 cells were fused with enucleated G0 cytoplasts
to create cells with two centrosomes, but only one diploid
nucleus (Figure 1F). The cell-cytoplast fusions were
released from G0 into BrdU-containing medium and
allowed to proceed through the cell cycle. The fused cells
were compared to cells in the population that had experi-
enced the fusion treatment but had not fused. At 24 h after
fusion, 66+/-15% of cytoplast-cell fusions with an extra
centrosome had entered S phase, and 63+/-11% of
unfused control cells had entered S phase. Therefore the
presence of an extra centrosome at G1 does not delay S
phase entry and is not responsible for the G1 arrest in
binucleate cells resulting from cytochalasin-induced fail-
ure of cytokinesis.
To test the role of tetraploidy, serum-starved HDF cells
were fused to create binucleate cells. Creating binucleate
cells by fusion avoided disruption of the actin cytoskele-
ton, allowing us to examine the effect of ploidy alone. The
binucleate cells resulting from fusion were both tetraploid
and had two centrosomes; we showed above that centro-
some number was not a factor in the G1 arrest. As above,
unfused cells in the population served as an internal con-
trol. At 24 h after fusion, 72+/-2% of the unfused cells and
75+/-1% of the fused, binucleate, cells had entered S
phase. Therefore, tetraploidy does not cause the observed
G1 arrest resulting from cytochalasin-induced failure of
cytokinesis.
Cells that fail to divide at cytokinesis are larger than nor-
mal cells. Larger cells have a decreased surface area to vol-
ume ratio, which might affect the response to
perturbation of the cytoskeleton. Thus, the apparent sen-
sitivity to cytokinesis failure might derive directly from a
difference in size. To test this, we created large binucleate
cells by fusing serum-starved G0 cells to each other. The
fusion products were released into growth medium for 3
h to allow for reattachment to the culture substrate. We
then added 25 µM blebbistatin, 5 µM cytochalasin, or 5
µM AKI-1 to cells for 10 h, followed by release into BrdU-
containing medium. Figure 2 shows that mononucleate
and binucleate cells in the control and drug-treated popu-
lations entered S phase with similar kinetics. Note that in
the cells treated with cytochalasin there was a significant
delay in S phase entry, consistent with the cytotoxicity of
cytochalasin that we and others have described [13].
These results demonstrate that binucleate cells are not
more sensitive to cytokinesis inhibitors due to their
increased size.
If cells were sensitive to failure of cytokinesis, one might
expect that the sensitivity would be expressed as a delay in
exit from mitosis, a time when a cytokinetic defect could
be corrected. This would be similar to the known DNA
damage, DNA replication and spindle assembly check-
points [16]. We tested in two ways whether mammalian
cells delay the exit from mitosis in response to cytokinesis
failure. First, HDF cells were imaged by time-lapse micro-
scopy as they progressed through mitosis in the presence
or absence of blebbistatin. Cells were synchronized in
mitosis by nocodazole treatment, then released for 30
min, when 25 µM blebbistatin was added. Control cells (n
= 5) exhibited cytokinetic constrictions beginning about
60 min after release from nocodazole. These cells flat-
tened and began to spread, signaling the end of mitosis,
about 85 min after release (Figure 3A). Blebbistatin-
treated cells (n = 9) did not undergo observable cytokine-
sis, as expected, but did flatten and spread about 110 min
after release from nocodazole (Figure 3A). We also tested
for a delay in mitotic exit by staining with MPM-2, and
antibody specific for mitotic phosphoepitopes [17]. Cells
that were MPM-2 positive and had condensed DNA were
considered to be in mitosis (Figure 3B). After release from
nocodazole arrest, the fraction of mitotic cells declined in
both the control and blebbistatin-treated populations
with only a slight delay apparent in the blebbistatin-
treated cells (Figure 3C). Both assays showed that bleb-
bistatin treatment resulted in only a brief delay in the exit
from mitosis, suggesting that failure of cytokinesis does
not trigger a checkpoint-like arrest.BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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Since we had ruled out most of the cellular defects associ-
ated with division failure as being the cause of the G1
arrest, we attempted to further characterize the arrest.
Andreassen et al. [6] reported that p53 is important in the
G1 arrest caused by cytokinesis failure. To test the role of
the p53 pathway, we repeated the blebbistatin experiment
above with wt, p53 -/-, and p21 -/- mouse embryonic
fibroblast (MEF) cells. Wt MEF cells behaved similarly to
the HDF cells, arresting in G1 in response to cytokinesis
failure (Figure 4A). However, in p53 -/- and p21 -/- MEF
cells both binucleate and mononucleate cells entered S
Cytokinesis inhibitors do not block the G1 to S phase progression of binucleate HDF cells Figure 2
Cytokinesis inhibitors do not block the G1 to S phase progression of binucleate HDF cells. Serum-starved G0 cells 
were fused and released into medium containing BrdU and (A) no drug, (B) 25 µM blebbistatin, (C) 5 µM AKI-1, or (D) 5 µM 
cytochalasin. Some cells remain unfused after the fusion treatment, and were used as mononucleate controls. Time points 
were taken to assay for S phase entry.BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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Cytokinesis failure does not significantly delay the exit frommitosis Figure 3
Cytokinesis failure does not significantly delay the exit frommitosis. (A) Images from time-lapse series of HDF cells at 
the indicated times after release from nocodazole-mediated mitotic arrest. "Control" cells were not treated with blebbistatin; 
"Blebbistatin" cells were treated with blebbistatin beginning at 30 min after release from nocodazole. (B) MPM-2 immunofluo-
rescence as a marker for mitotic exit. Fluorescence image of a mitotic cell with condensed DNA and intense MPM-2 staining 
(top) and a cytokinetic cell with decondensed DNA and diminished MPM-2 staining (bottom). DNA, blue; MPM-2, green. Scale 
bar represents 10 µm. (C) Mitotic index of control and blebbistatin-treated cells after mitotic release. "Control" cells were not 
treated with blebbistatin; "Blebbistatin" cells were treated with blebbistatin beginning at 30 min after release from nocodazole. 
Mitotic index was determined by MPM-2 staining and DNA morphology, as in (B). For each point n = 100 cells.BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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Cells arrested in G1 by cytokinesis failure enter p53- and p21-dependent premature senescence Figure 4
Cells arrested in G1 by cytokinesis failure enter p53- and p21-dependent premature senescence. (A) p53 path-
way dependence of the G1 arrest following cytokinesis failure. Wt, p53-/- and p21-/- mouse embryo fibroblasts were synchro-
nized and treated with blebbistatin and assayed as in Figure 1E. For each bar n ≥ 200 cells. (B) G1 arrested binucleate cells 
entered premature senescence as assayed by senescence-associated β-galactosidase activity (SA-β-gal). The dark stain in the 
binucleate cell shown is the reaction product of Xgal cleavage. Scale bar represents 10 µm. (C) Time course of appearance of 
senescent cells. Mononucleate and binucleate cells were assayed for SA-β-gal at the indicated days after blebbistatin removal. 
For each point n = 60–100 cells.BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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phase with the same kinetics (Figure 4A). Thus, the p53-
p21 pathway is required for the G1 arrest of binucleate
cells.
p53-p21-dependent G1 arrest often results in either apop-
tosis or senescence [18,19]. To determine the fate of the
G1-arrested products of a failed cytokinesis, binucleate
HDF cells were prepared using blebbistatin as described
above. Blebbistatin was then removed and the cells were
assayed by microscopy. The binucleate cells persisted in
the population over the course of more than two weeks,
consistent with these cells being permanently arrested in
the cell cycle. The binucleate cells did not undergo apop-
tosis, as assayed by morphology and staining with
annexin V, an early marker of apoptosis (not shown).
However, the binucleate cells did develop several hall-
marks of senescence, including becoming flattened and
enlarged, and accumulating senescence-associated β-
galactosidase activity (Figure 4B). As the criteria for defin-
ing cellular senescence are not firmly established [20], we
will refer to this phenotype as "senescent-like". At 4 days
after blebbistatin removal approximately 35% of binucle-
ate cells and 10% of mononucleate cells were senescent-
like; by 12 days virtually all of the binucleate cells, but
only 10% of mononucleate cells, were senescent-like (Fig-
ure 4C).
We have shown that failure of division of synchronized
cells results in a p53-dependent arrest, but that the arrest
is not due to ploidy, centrosome number, or cell size, and
that the arrest is not preceded by a delay in mitotic exit,
suggesting that it is not a classical checkpoint. The charac-
teristics of the arrest are similar to those of the G1 arrest
caused by the DNA damage checkpoint in HDF cells,
which respond to irreparable DNA damage by entering
senescence, instead of apoptosis [21]. These similarities
led us to test whether the binucleate G1 arrest might actu-
ally be due to DNA damage suffered during the treatment.
Cells were synchronized in mitosis by the double thymi-
dine – nocodazole regimen described above and treated
with 25 µM blebbistatin. The binucleate cells were
released from blebbistatin for 1 h, 3 days, and 8 days
respectively, then stained for γ-H2AX, a marker of DNA
damage [22]. As a positive control for DNA damage, asyn-
chronous cells were treated with 1 mM hydrogen peroxide
for 30 min, allowed to recover in medium for 1 h, and
stained for γ-H2AX.
In the untreated control cells, only 3.4% of cells contained
γ-H2AX foci, whereas in the hydrogen peroxide treated
cells, 33% of cells contained γ-H2AX foci (Figure 5A).
Remarkably, at 1 h after release of synchronized cells from
blebbistatin, 52% of the binucleate cells contained γ-
H2AX foci in one or both nuclei (Figure 5A), suggesting
the presence of DNA damage. However, we found that
32% of the mononucleate cells that successfully
completed cytokinesis after blebbistatin treatment also
contained γ-H2AX foci. This suggested that the observed
DNA damage might not be the result of division failure
per se, and therefore might have occurred prior to the
addition of blebbistatin, possibly during cell synchroniza-
tion. At 3 days after release from blebbistatin, 30% of the
binucleate cells and 11% of the mononucleate cells con-
tained visible γ-H2AX foci. At 8 days after release from
blebbistatin, 29% of the binucleate cells and only 6% of
the mononucleate cells contained γ-H2AX foci. Most of
the binucleate cells also displayed senescent-like pheno-
types at 8 days after the removal of blebbistatin (Figure
5B).
The binucleate cells that persisted in culture were arrested
in G1, as they did not incorporate BrdU after the previous
round of mitosis, and they did not proceed to the next
round of mitosis, as evidenced by the preservation of the
binucleate phenotype. The presence and persistence of
nuclear γ-H2AX foci in the G1-arrested binucleate cells
suggested that DNA damage might be the cause of the
arrest. However, not all the arrested binuclear cells con-
tained visible γ-H2AX foci, indicating that γ-H2AX-associ-
ated DNA damage might not be the only cause of the
arrest. The percentage of binucleate cells with nuclear γ-
H2AX decreased from 52% to 29% over 8 days of cultur-
ing, possibly indicating that some cells were able to cor-
rect the DNA damage after being arrested in G1 for several
days. In contrast, the percentage of mononucleate cells
that displayed γ-H2AX foci decreased dramatically over 8
days of culturing, however this was likely due to prolifer-
ation of normal mononucleate cells in the culture rather
than a difference in response of the mononucleate and
binucleate cells to the treatment.
The presence of γ-H2AX foci in the mononucleate cells
that successfully completed cytokinesis after blebbistatin
treatment suggested that the DNA damage might have
been the result of the synchronization treatments, prior to
the addition of blebbistatin. Therefore, we tested whether
any of the cell synchronization treatments alone had an
effect on cell cycle progression. Asynchronous cells were
treated with double thymidine block, nocodazole, or
blebbistatin individually, following the same protocols
used above in multiple treatments. Cells were released
from drug and S phase entry was assayed at time points.
Figure 6A shows that none of the drug treatments resulted
in a substantial failure of cell cycle progression after
release. Most importantly, we found that most of the
binucleate cells that resulted from cytokinesis failure with
blebbistatin treatment alone were able to enter S phase
normally after release. This result indicates that there is no
cytokinesis checkpoint, in accord with the results of
Uetake and Sluder [9].BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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Binucleate cells contain nuclear γ-H2AX foci Figure 5
Binucleate cells contain nuclear γ-H2AX foci. (A) Binucleate cells were prepared by synchronization and treatment with 
25 µM blebbistatin as described above, then stained for the DNA damage marker γ-H2AX. Untreated control cells (top) did 
not contain any visible γ-H2AX foci, whereas binucleate cells, after released from blebbistatin for 1 h, (bottom) contained γ-
H2AX foci that were similar to those of cells treated with H2O2 (middle). Scale bar represents 2.5 µm. (B) Culture was contin-
ued for 8 days after release from blebbistatin. Most mononucleate cells lacked γ-H2AX foci (top), whereas approximately 30% 
of binucleate cells still contained nuclear γ-H2AX foci (bottom). The binucleate cells were also flattened and enlarged, consist-
ent with a senescent-like arrest. Scale bar represents 10 µm.BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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Since none of the single drug treatments resulted in a cell
cycle arrest, we reasoned that some combination of the
treatments must be responsible. To determine which com-
bination of treatments caused a G1 arrest, cells were sub-
jected to the treatments in the order double thymidine,
nocodazole, blebbistatin. Samples of cells were taken after
release from each drug, and S phase entry was assayed
(Figure 6B). Although neither double thymidine nor
The combination of double thymidine block and nocodazole treatment causes DNA damage in HDF cells Figure 6
The combination of double thymidine block and nocodazole treatment causes DNA damage in HDF cells (A) 
Asynchronous HDF cells were treated with either double thymidine, nocodazole, or blebbistatin individually, then released 
into BrdU-containing growth media and assayed for S phase entry. For each bar n ≥ 200 cells. (B) Cells were subjected to the 
treatments in the order double thymidine, nocodazole, blebbistatin. Samples of cells were taken after release from each drug, 
and S phase entry was assayed. For each bar n ≥ 200 cells. (C) Cells were treated with double thymidine block followed by 
nocodazole, then stained for γ-H2AX. Scale bar represents 2.5 µm.BMC Cell Biology 2005, 6:6 http://www.biomedcentral.com/1471-2121/6/6
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nocodazole arrest and release alone resulted in a G1
arrest, the combination of them did; only about 45% of
such cells progressed into S phase. The addition of bleb-
bistatin to the treatment did not cause a further reduction
in the fraction of cells entering S phase; about 64% of the
mononucleate cells progressed into S phase. However,
only about 22% of the binucleate cells that failed cytoki-
nesis after blebbistatin treatment progressed into S phase.
This indicated that the G1 arrest in our experiments is due
to the double thymidine block, followed by nocodazole
treatment, and that binucleate cells are more susceptible
to this effect.
To determine whether the thymidine – nocodazole com-
bination caused the DNA damage we observed, cells were
treated with both drugs as above and stained for γ-H2AX.
At 3 h after release from the drug treatments, about 33%
of cells had γ-H2AX foci (Figure 6C). Thus the thymidine
– nocodazole synchronization treatment caused the DNA
damage that resulted in cells becoming arrested in G1.
Given these results we suggest a simple model for the
increased susceptibility of binucleate cells: those cells that
failed cytokinesis are more likely to become arrested in G1
because they contain two nuclei, and thus have twice the
chance of inheriting DNA damage compared with cells
that successfully divided.
Conclusions
We have shown that tetraploidy, aberrant centrosome
number, increased cell size, and failure of cytokinesis do
not lead to G1 arrest in primary human diploid
fibroblasts. Rather, we found that the observed G1 arrest
in cells that have failed to divide is likely due to cellular
damage caused by standard synchronization treatments.
We note that all published observations of a G1 arrest in
response to division failure involved extensive manipula-
tion of mammalian cells in culture. It seems likely that
these manipulations resulted in DNA damage, or in other
damage, that resulted in a G1 arrest, but was not directly
associated with division failure. For example, Uetake and
Sluder [9] found that supplementing the culture substrate
with fibronectin allowed binucleate cells formed by cyto-
chalasin treatment to progress through the cell cycle, sug-
gesting that cell adhesion was defective in the drug-treated
cells. Given that binucleate cells clearly can cycle when
formed with minimal manipulation, it is likely that all
previous reports of a tetraploidy checkpoint can be
explained by side effects of the drug treatments used to
observe them.
Methods
Cell methods
Human diploid fibroblasts (HDFs) were from infant fore-
skin. Wt, p53 -/- and p21 -/- mouse embryo fibroblasts
(MEFs) were the kind gift of Laura Attardi (Stanford, CA).
HDFs and MEFs were cultured in DMEM (Gibco) with
10% fetal bovine serum. HDFs were used prior to passage
10 and MEFs were used prior to passage 5. HDFs were syn-
chronized in G0 by serum starvation [12] and S phase by
double thymidine block [23], as described. In the cell
fusion experiments, serum-starved G0 cells, or cytoplasts
derived from those cells by centrifugation, were fused
with serum-starved G0 cells, as described [12]. Immuno-
cytochemistry was as described [12]. Live cell imaging was
with a Nikon Diaphot microscope equipped with an envi-
ronmental chamber allowing incubation at 37°. Images
were collected with a CCD camera (Photometrics) and
processed with Openlab (Improvision) and Photoshop
(Adobe) software. Senescence-associated β-galactosidase
activity (SA-β-gal) was assayed as described [24].
Assay for S phase entry by BrdU incorporation
Cells were incubated with 20 µM BrdU (Sigma) for indi-
cated times and fixed in -20°C methanol for at least 10
min. Fixed cells were treated with DNase I (Boehringer
Mannheim) and exonuclease III (New England Biolabs)
to expose the BrdU epitope prior to incubation with anti-
BrdU antibodies, as described [12]. Nuclei were visualized
by staining 4',6-diamidino-2-phenylindole (DAPI). Cells
were observed with a Zeiss Axioskop microscope with a
Zeiss Plan-Neofluar 100/1.3 objective, and images were
collected with a cooled-CCD camera (Hamamatsu) con-
trolled by Openlab software.
Assay for DNA damage by γ-H2AX staining
Cells were fixed with 2% paraformaldehyde at room tem-
perature for 10 min, washed 3× with PBS, then permeabi-
lized with-20°C methanol for 5 min and stained with 27
ng/ml γ-H2AX antibody (Trevigen, MD). Only cells with
multiple, clearly labeled foci were counted as being γ-
H2AX positive.
Drug-induced cytokinesis failure
Cells synchronized in S phase by double thymidine block
were released from the block for 6 h to allow completion
of S phase. Nocodazole (100 ng/ml) (US Biological) was
then added for 6 h to arrest the cells in mitosis. Cells were
released from the mitotic arrest for 30 min, during which
time most cells formed a bipolar mitotic spindle (Fig 1B).
At 30 min after release from mitotic arrest, 20 µM BrdU
was added to the medium, together with the indicated
concentration of cytochalasin B (Sigma) or (s)-(-)-bleb-
bistatin (Toronto Research Chemicals). Cells were incu-
bated in this medium for 10 h to inhibit cytokinesis, then
changed to growth medium containing 20 µM BrdU but
no cytokinesis inhibitor, and assayed for S phase entry at
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